ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1881

In Radiographic Axial Spondyloarthritis, Bridging Syndesmophytes Increase Risk of Facet Joint Ankylosis Development on the Same Vertebral Level While Facet Joint Ankylosis Does Not Increase Risk of Same Level Syndesmophytes Development
Abstract Number: 0565

In Those with Unilateral Frequent Knee Pain, Between-Limb Differences in Stance Time During Walking Increase the Risk of Frequent Pain in the Other Knee: The MOST Study
Abstract Number: 0347

In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Abstract Number: 0450

In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition
Abstract Number: 1705

In-Person Musculoskeletal Exam Demonstration by Rheumatologist More Effective Than Virtual PowerPoint Presentation in Teaching Internal Medicine Residents
Abstract Number: 0898

Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Therapy in a Real-world US Commercially Insured Population
Abstract Number: 0564

Incidence and Progression of Foot Osteoarthritis
Abstract Number: 2002

Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib
Abstract Number: 0215

Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program
Abstract Number: 0277

Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria
Abstract Number: 0467

Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab
Abstract Number: 0488

Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database
Abstract Number: 0548

Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up
Abstract Number: 0114

Incidence of Follow-Up Dual-Energy X-Ray Absorptiometry Scanner Error: A Contributor to Precision Error
Abstract Number: 0183

Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].